Literature DB >> 17678956

The high-mobility group box 1 cytokine induces transporter-mediated release of glutamate from glial subcellular particles (gliosomes) prepared from in situ-matured astrocytes.

Giambattista Bonanno1, Luca Raiteri, Marco Milanese, Simona Zappettini, Edon Melloni, Marco Pedrazzi, Mario Passalacqua, Carlo Tacchetti, Cesare Usai, Bianca Sparatore.   

Abstract

The multifunctional protein high-mobility group box 1 (HMGB1) is expressed in restricted areas of adult brain where it can act as a proinflammatory cytokine. We report here that HMGB1 affects CNS transmission by inducing glutamatergic release from glial (gliosomes) but not neuronal (synaptosomes) resealed subcellular particles isolated from mouse cerebellum and hippocampus. Confocal microscopy showed that gliosomes are enriched with glia-specific proteins such as GFAP and S-100, but not with neuronal proteins such as PSD-95, MAP-2, and beta-tubulin III. Furthermore, gliosomes exhibit labeling neither for integrin-alphaM nor for myelin basic protein, specific for microglia and oligodendrocytes, respectively. The gliosomal fraction contains proteins of the exocytotic machinery coexisting with GFAP. Consistent with ultrastructural analysis, several approximately 30-nm nonclustered vesicles are present in the gliosome cytoplasm. Finally, gliosomes represent functional organelles that actively export glutamate when subjected to releasing stimuli, such as ionomycin or ATP, by mechanisms involving extracellular Ca(2+) and Ca(2+) release from intracellular stores. HMGB1-induced release of the stable glutamate analogue [(3)H]d-aspartate and endogenous glutamate form gliosomes, whereas nerve terminals were insensitive to the protein. The HMGB1-evoked release of glutamate was independent on modifications of cytosolic Ca(2+) concentration, but it was blocked by dl-threo-beta-benzyloxyaspartate, suggesting the involvement of transporter-mediated release mechanisms. Moreover, dihydrokainic acid, a selective inhibitor of glutamate transporter 1 does not block the HMGB1 effect, indicating a role for the glial glutamate-aspartate transporter (GLAST) subtype in this response. HMGB1 bind to gliosomes but not to synaptosomes and can physically interact with GLAST and receptor for advanced glycation end products (RAGE). Taken together, these results suggest that the HMGB1 cytokine could act as a modulator of glutamate homeostasis in adult mammalian brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678956     DOI: 10.1016/S0074-7742(07)82004-6

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  8 in total

Review 1.  HMGB1 is a therapeutic target for sterile inflammation and infection.

Authors:  Ulf Andersson; Kevin J Tracey
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

2.  Increased high-mobility group box 1 levels are associated with depression after acute ischemic stroke.

Authors:  Wanying Shan; Liang Xu; Zhuoyin Qiu; Jingwen Wang; Jiaxing Shao; Jie Feng; Jie Zhao
Journal:  Neurol Sci       Date:  2021-11-20       Impact factor: 3.830

Review 3.  Targeting HMGB1 in inflammation.

Authors:  Huan Yang; Kevin J Tracey
Journal:  Biochim Biophys Acta       Date:  2009-12-03

Review 4.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 5.  High-mobility group protein box-1 and its relevance to cerebral ischemia.

Authors:  Qing-wu Yang; Jing-Zhou Wang; Jing-Cheng Li; Yu Zhou; Qi Zhong; Feng-Lin Lu; Jing Xiang
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-30       Impact factor: 6.200

Review 6.  Extracellular high-mobility group box 1 protein (HMGB1) as a mediator of persistent pain.

Authors:  Nilesh M Agalave; Camilla I Svensson
Journal:  Mol Med       Date:  2015-02-05       Impact factor: 6.354

7.  A Comparative Metabolomic Evaluation of Behcet's Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid.

Authors:  Joong Kyong Ahn; Sooah Kim; Jungyeon Kim; Jiwon Hwang; Kyoung Heon Kim; Hoon-Suk Cha
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

8.  Serum Metabolomic Profiling of Patients with Non-Infectious Uveitis.

Authors:  Hiroyuki Shimizu; Yoshihiko Usui; Masaki Asakage; Naoya Nezu; Ryo Wakita; Kinya Tsubota; Masahiro Sugimoto; Hiroshi Goto
Journal:  J Clin Med       Date:  2020-12-06       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.